Head-to-head · WeighScore
NextMeds vs Shapely
The verdict
NextMeds takes it — 66.1/100 to 65.4/100, but only just.
NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a… Shapely is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | NextMeds | Shapely |
|---|---|---|
| WeighScore | 66.1/100 | 65.4/100 |
| Grade | C | C |
| Scorecard rank | #207 | #225 |
| Semaglutide | $129/mo (plus a separate fee, compounded) | Not disclosed |
| Tirzepatide | $179/mo (plus a separate fee, compounded) | Not disclosed |
| Coverage | All 50 states | 4 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #207 · C
Strengths
- Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
- Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
- Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
- Free, no-obligation online assessment before you pay anything
Where it loses points
- Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
- Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
- A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #225 · C
Strengths
- Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
- Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
- Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
- 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
- Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program
Where it loses points
- Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
- Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
- Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
- No LegitScript certification found on any public page
- Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.